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The development of ventricular assist devices has broadened the means with which one can treat acute heart failure. Percutaneous
ventricular assist devices (pVAD) have risen from recent technological advances. They are smaller, easier, and faster to implant, all
important qualities in the setting of acute heart failure. The present paper brieﬂy describes the functioning and assets of the most
common devices used today. It gives an overview of the current evidence and indications for left ventricular assist device use in
cardiogenic shock and high-risk percutaneous coronary intervention. Finally, extracorporeal life support devices are dealt with in
the setting of hemodynamic support.
1.Introduction
Severe heart failure whether acute or chronic is a stren-
uous clinical challenge. Noninvasive management through
inotropic support allows frequent clinical improvement, yet
one is repeatedly confronted with refractory cases necessitat-
ing more invasive support.
The idea of a mechanical assistance ﬁrst appeared in
the 1950s, yet the ﬁrst device which is the intra-aortic
balloon pump (IABP) only appeared in the late 1960s. It
remains, today, the most common, cheapest, and easily
available cardiac mechanical device. The most frequent use
of IABP is cardiogenic shock with data accounting for
20% of all insertions [1]. It is eﬀective in the stabilization
of patients, but it does not provide full cardiac support,
and improvement of outcome has not been demonstrated
[2]. Hemodynamically, it achieves a maximum of increase
of cardiac output of 0.5L/min. Moreover, its reliance is
dependant by the intrinsic cardiac function as well as
stable rhythm. In light of these facts, growing interest
and expertise have been invested in the development of
devices thought to supplement the failing heart. Today, a
large pallet of ventricular assist devices is used for a wide
range of indications; from long-term replacement of failing
hearts to bridge-to-transplantation but also, and foremost,
in the temporary support of cardiogenic shock (bridge-to-
recovery)anditsprophylacticuseincertaininvasivecoronary
or valvular procedures.
One diﬀerentiates between long- and short-term as well
as surgically implanted versus minimally invasive percuta-
neous ventricular assist devices (pVAD). The latter have the
advantage of availability, simplicity of use, and installation.
The present review will concentrate on the two pVADs that
have received FDA and CE approval for clinical use, the
TandemHeart (Cardiac Assist Inc., Pittsburgh, PA, USA) [3]
and the Impella Recover LP 2.5 (AbioMed, Europe, Aachen,
Germany) [4]( Figure 1). It also includes a section on the use
of extracorporeal life support in cardiogenic shock.
2.DeviceSpeciﬁcities,
Implantation, andComplications
The TandemHeart creates a percutaneous left atrial-to-
aortal shunt. Within no more than half an hour, blood is
collected from the left atrium, directed to an extracorporeal
pump, and then redirected to the abdominal aorta. An
operatorwelltrainedintransseptalpunctureshouldperform
TandemHeart implantation. After gaining femoral venous
access, transseptal puncture is performed using standard2 Minimally Invasive Surgery
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Figure 1: Schematic representation of two commercially available percutaneous ventricular assist devices (VAD). (a) The TandemHeart
pVAD consists of a 21F left atrial inﬂow cannula, an extracorporeal centrifugal pump rotating at up to 7500rpm, a femoral outﬂow cannula
(15F–17F) that extends into the iliac artery, and a microprocessor-based pump controller, which can provide blood ﬂow up to 4L/min.
The tip of the atrial drainage cannula is positioned under ﬂuoroscopic guidance into the left atrium following transseptal puncture. (b) The
Impella LP 2.5 is a catheter-mounted device. The microaxial pump consists of an impeller driven by an integrated microelectric motor on
the distal end of a ﬂexible catheter. At a maximum speed of 33,000rpm, the pump provides a maximum hydraulic capacity of 2.5L/min.
The Impella Recover LP 2.5 is retrogradely placed across the aortic valve into the left ventricle where it aspirates blood via a caged blood ﬂow
inlet which is then ejected into the ascending aorta.
Brockenbrough technique. When undertaken under car-
diopulmonaryresuscitation,externalcardiacmassageshould
be brieﬂy stopped during a few seconds in order to allow
the operator to perform atrial septum puncture. Then,
the interatrial septum is dilated using a two-stage (14–21
French) dilator to accommodate the 21-French (Fr) left
atrial drainage cannula. Using the Seldinger technique, a 15–
17-Fr femoral artery cannula is placed retrogradely in the
iliac artery. Both cannulae are connected to the centrifugal
pump under careful evacuation of any air within the tubing.
The centrifuge is powered by a microprocessor-controlled
electromechanical unit, which enables rotation at 3,500 to
7,500 rotations per minute (rpm). The 15-Fr cannula allows
a maximal estimated ﬂow of 3.5L/min and the 17-Fr 4
to 5L/min depending on systemic vascular resistance. The
pump’s eﬃcacy also depends on the proper suction of blood
from the left atrium, which could be impaired by wedging of
the cannula against the atrial wall in case of deep position
of the cannula or inappropriate ﬁlling of the left atrium.
Special care must be taken to avoid displacement or kinking
of the inﬂow cannula, particularly the dislodgement of the
cannula from the left into the right atrium. The latter will
result in loss of oxygenation and functionally corresponds to
a right-to-left shunt. Therefore, the inﬂow cannula needs to
be secured and immobilized in order to minimize the risk of
dislodgement.
Duration of support classically extends from hours to
15 days. When appropriate, a stepwise weaning process (for
instance by 500mL/minute every hour) should be initiated.
Weaning criteria are usually met when cardiac index and
mean arterial pressure exceed 2.0L/min/m2 and 70mmHg,
respectively, in the absence of end-organ hypoperfusion
and without inotropic support. Hemostasis is achieved
by manual compression but owing to the large cannula,
surgical closure is frequentlyneeded. In comparison, a rather
frequent complication (18% of patient with cardiogenic
shock at our institution) using the TandemHeart is arterial
occlusion and subsequent limb ischemia [5]. Owing to
the transseptal puncture, atrial septal defect may persist.
Aortic puncture is extremely rare and pericardial tampon-
ade seldom occurs. Finally, particular caution should be
made in patients with signiﬁcant right ventricular failure.
Implantation of left-sided TandemHeart might precipitate
hemodynamic collapse and death.
The Impella Recover left percutaneous LP 2.5L/min is
a 12-Fr axial ﬂow pump that works on the principle of
an Archimedes screw. The impeller is inserted retrogradely
through the femoral artery via a 13-Fr peel-away sheath.
A 5-Fr Judkins is used to pass through the aortic valve
into the left ventricle. The 12Fr device is then inserted
to draw blood out of the left ventricle into the ascending
aorta. At maximum speed of 50,000rpm the pump provides
an output of 2.5L/min. Nine intensities can be adjusted,
allowing subtle support. At minimum speed, the pump
compensatestheaorticregurgitationinducedbythecatheter.
Hemostasis is made by manual compression. The supportMinimally Invasive Surgery 3
is weaker than with TandemHeart and usually of shorter
duration (from hours up to ﬁve days at our institution).
However, implantation due to single arterial puncture and
familiar technique is faster than TandemHeart. Another is
advantage is the absence of transseptal puncture as well as
extracorporeal blood ﬂow. Arterial occlusion is infrequent
but haemolysis complicated up to 1/5 of patients and
typicallyoccurswithintheﬁrst48hoursaftersupportbegins.
A similar version, the Impella LP 5.0, achieves a 5L/min
output. The latter requires a surgical procedure [6, 7].
Prior to implantation of either device, angiography of
the aorta, iliac, and femoral vessels is mandatory in order
to evaluate vessel diameter, presence of obstruction, or
disproportionate tortuosity (Figure 2). Both pVADs require
anticoagulation with heparin at therapeutic levels with
recommended activated clotting time of 250sec during the
procedure and 200sec during support phase.
Ventricular arrhythmia may complicate the implantation
of Impella owing to its intraventricular positioning. A com-
plication common to both pVADs is thrombocytopaenia.
Myocardial infarct, atrial cannulation, severe ventricular
dysfunction, and postprocedural haemorrhage all contribute
toathromboembolicrisk.Infectionsareusuallyseeninlong-
term cardiac assist devices rather than pVADs [8].
Relative contraindications to both pVADs are severe
aortic regurgitation, prosthetic aortic valve, as well as aortic
aneurysm or dissection. Severe peripheral vascular disease,
left ventricular and/or atrial thrombi, severe coagulation
disorders, and uncontrolled sepsis further preclude their use.
3. Indications
Cardiogenic shock and high-risk percutaneous coronary
intervention (PCI) are two possible indications for percuta-
neous left ventricular assist devices (Figure 3).
3.1. Cardiogenic Shock (CS). Classically, it is deﬁned on the
basisofhemodynamicparametersincludingsystolicsystemic
blood pressure (sSBP) <90mmHg for more than 30min,
cardiac index (CI) of <2.2L/min/m2, pulmonary capillary
wedge pressure (PCwP) >15mmHg, and in patients with
hypertension a reduction in usual sSBP of >30mmHg [9].
More importantly it is when cardiac output is severely
diminished and responsible for end-organ dysfunction. This
enhances neurohumoral responses and systemic inﬂam-
matory response syndrome (SIRS) further aggravating the
cardiac dysfunction. The incidence of CS in ST-elevated
myocardial infarct is unchanged at around 7% [10]a n d
mortality is frighteningly high at 60% despite advances in
pharmacological treatment and reperfusion therapy [11].
The beneﬁt expected from the implantation of pVADs
is alleviation of the strained cardiac muscle and immediate
restoration of cardiac output with physiological organ per-
fusion, thus breaking the vicious cycle of harmful neuro-
humoral responses and cytokine production. Evaluating the
eﬃciencyintermsofevidence-basedmedicineisproblematic
considering the small number of patients who beneﬁt from
such therapy. However, patient-based, pVAD implantation
(a) (b)
(c) (d)
Figure 2: Examples of angiographic assessment prior to percu-
taneous ventricular assist device implantation. (a)–(d). Suitable
anatomy with increasing amount of calciﬁcation, plaque, and
tortuosity.
is undoubtedly life saving and numerous case reports show
successful outcomes [12–14].
Regarding hemodynamic parameters, evidence shows
increased cardiac outputs between 37 to 43% with both
pVADsaswellasa38%decreaseinPCwP[15,16].Clinically,
the earlier the assistance is initiated the better the outcome
with mortality of 26% when pVADs are initiated in the ﬁrst 2
weeksasopposedto40%after2weeks[17].Notsurprisingly,
outcomeisworstincaseofbiventricularfailurewithweaning
from pVADs decreasing from 73% in left ventricular failure
to 53% in biventricular failure [18].
Both TandemHeart and Impella Recover LP 2.5 have
been compared to IABP. Two randomised trials have eval-
uated the TandemHeart in comparison to IABP in patients
with CS primarily due to acute myocardial infarction [15,
19].Inboth,pVADimprovedcardiacindexandreducedpul-
monary capillary wedge pressure signiﬁcantly. Importantly
there was no diﬀerence in mortality and the trials were not
designed or powered to assess survival diﬀerences. Compli-
cations such as limb ischemia and severe haemorrhage were
more frequent in the pVAD group than the IABP group. One
randomised trial compared the Impella Recover LP 2.5 to
IABP [20]. Again, cardiac output was signiﬁcantly improved
in the ﬁrst group, and there were no diﬀerences with respect
to 30-day mortality.
Kar et al. have recently demonstrated the use of Tandem-
Heartinsevererefractorycardiogenicshockofbothischemic
and nonischemic origin [21]. In this observational study,
117 patients under IABP and/or high-dose vasopressors were
implanted with a TandemHeart, 56 of which underwent
active cardiopulmonary resuscitation. Mortality rate at 30
days was 40.2% and 45.3% at 6 months. These are sig-
niﬁcantly lower than the ranges accounted for in previous4 Minimally Invasive Surgery
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Figure 3: Schematic clinical uses of percutaneous ventricular assist devices (VAD). PCI: percutaneous coronary intervention, ACLS: acute
cardiac life support, IABP: intra-aortic balloon pump, pVAD: percutaneous ventricular assist device, sVAD: surgical ventricular assist device,
ECLS: extracorporeal life support. Utility of pVADs stretches from prophylactic use in high-risk PCI to immediate life-saving implantation
during cardiopulmonary arrest. In cardiogenic shock especially after myocardial infarction, clinical assessment is necessary and current
guidelinesfavourinotropicsupportwithIABPcounterpulsation.pVADorECLSimplantationcompletesthemanagementwhenthenpatient
deteriorates . In case of further decline one should think of sVAD as well as heart transplantation.
trials such as the Shock Trial registry. As in previous trials,
complications were frequent, amongst which haemorrhage
and limb ischemia.
The Euroshock registry has evaluated the use of Impella
Recover2.5in120patientswithcardiogenicshockafteracute
myocardial infarction [22]. Overall 30-day mortality was
64.2%. The initial hemodynamic proﬁle of patients was poor
when compared to other studies reﬂecting the last-resort
use of pVAD. Age over 65 and plasma lactate at admission
>3.8mmol/L were demonstrated to be signiﬁcant predictors
of 30-day mortality. Major cardiac and cerebral events were
reported in 15% of patients.
Although encouraging, these data preclude the use of
pVADs as ﬁrst-line mechanical therapy in cardiogenic shock
[23].
3.2. Bridging. Signiﬁcant evidence shows pVAD utility in
the bridge-to-recovery concept [24, 25]. This being when
the assistance device supports the failing heart in potentially
reversible causes of shock such as myocarditis, drug over-
dose, hypothermia, coronarography-related complications
(air embolism, no-reﬂow phenomenon, and dissections),
incessant arrhythmia, or postcardiotomy syndrome. Sim-
ilarly, pVADs are reliable and used until more deﬁnitive
measures can be undertaken such as long-term surgical
device implantation (bridge-to-bridge) and transplantation
(bridge-to-transplantation)[ 26, 27].
3.3. High-Risk Percutaneous Coronary and Valvular Inter-
ventions. Patients with complex coronary artery disease or
u n p r o t e c t e dl e f t - m a i nc o r o n a r ya r t e r ya sw e l la ss e v e r el e f t
main coronary stenosis occasionally present with hemody-
namic instability or suﬀer from such comorbidities that they
are considered ineligible for coronary artery bypass graft
(CABG). Correspondingly, they are at increased risk for
Table 1: Early clinical outcome in (A) patients with cardiogenic
shock and treated with surgical or percutaneous ventricular assist
device (s- or pVAD) and (B) in patients after preventive pVAD
implantation for high-risk percutaneous coronary intervention
(PCI).
Device N of patients 30-day survival
A. (Cardiogenic
shock)
sVADa 157 92 (59%)
pVADb 102 65 (64%)
B. (High-risk PCI) pVAD THc 113 94 (83%)
pVAD IPd 152 59 (78%)
TH means TandemHeart, IP is for Impella Recover 2.5LP; (a) pooled data
from 11 trials [17, 28–37], (b) pooled data from 11 trials [5–7, 15, 19, 38–
43], (c) pooled data from 11 trials [44–54], and (d) pooled data from 10
trials [55–64].
hemodynamic collapse during PCI. Preemptive IABP coun-
terpulsation implantation and even cardiopulmonary bypass
have been used to anticipate cardiopulmonary collapse
management. Recently, investigators have implanted pVADs
with the idea of a better supplementation owing to increased
cardiac output. Other pathologies necessitating support are
critical aortic stenosis and severe cardiomyopathy.
The ﬁrst study to have addressed this question showed
no signiﬁcant unloading of the left ventricle [55]. Recently,
hemodynamic studies of 11 patients undergoing high-
risk PCI with pre-emptive Impella insertion have shown
promising results. There was signiﬁcant left-ventricular
unloading as well as decreases in end-diastolic wall stress and
improvement in diastolic compliance [65].
So far, there is no randomised control trial, but many
observational, retrospective studies show safety of use, little
device complications, and lower than predicted mortality
at 30 days [56, 66, 67]. Table 1 summarizes the in-hospital
survival of patients having undergone high-risk PCI withMinimally Invasive Surgery 5
pVAD implantation. It also shows in-hospital survival of
patients with cardiogenic shock due to acute myocardial
infarction treated with either surgical or percutaneous
ventricular assist devices.
The Europella Registry published a retrospective study
with 144 patients. Thirty-day mortality was 5.5%. 6.2%
of patients had bleeding and 4% vascular complications
[68]. Recently, a randomised controlled study, Protect II,
compared the use of IABP to Impella Recover 2.5 in high-
riskPCIin305patients.Abiomedstoppedthetrialattheend
of 2010 after determining it could not reach its composite
primary end-point of 10 major adverse events. Provisional
results failed to demonstrate the superiority of the Impella
Recover 2.5 LP [69].
Therefore, the prophylactic use of pVADs in high-risk
PCI and other interventions, however appealing, should be
considered with caution until further evidence is published.
3.4. Ventricular Tachycardia Ablation. VT ablation is increas-
ingly performed particularly in patients with structural heart
disease, for symptom management or in the case of frequent
ICD shocks. In the hemodynamically unstable patient,
substrate-basedapproachesallowsuccessfulablationwithout
inducing arrhythmia. However, when this approach fails it
may be diﬃcult if not impossible to ablate hemodynamically
unstable arrhythmias. A number of case reports demonstrate
the beneﬁt of pVADs to achieve hemodynamic stability and
allow successful procedures. TandemHeart was ﬁrst used in
2007 as a support for VT ablation in a 55-year-old man
[70]. Later, unstable VT ablation was successfully achieved
in 3 patients using Impella Recover 2.5 LP support [71].
Furthercasereportshavebeenpublishedincludingtheuseof
pVADs in other types of arrhythmias such as unstable supra-
ventricular tachycardias in the setting of congenital heart
disease [72, 73].
4. Right Ventricularand
BiventricularAssistance
Acute right ventricular (RV) myocardial infarction may
result in ventricular wall dysfunction and dramatic eﬀects on
biventricular performance. Transpulmonary cardiac output
is diminished thereby compromising left ventricular (LV)
preload resulting in overall diminished cardiac output.
The RV dilates and pericardial pressure increases, changing
LV compliance via ventricular interdependence. Classically,
managementotherthanrapidreperfusionconsistsofvolume
resuscitation and inotropic support. Little is known on the
use of pVADs in RV failure and, as noted above, left-sided
pVAD such as TandemHeart are contraindicated in this
setting as they aggravate the fragile hemodynamic equi-
librium. However, dedicated TandemHeart cannulae have
been developed for the right ventricle (pRVAD). One initial
case report demonstrated the feasibility of pRVAD with
Tandem Heart [74]. Another case report shows successful
3-day support with an adapted TandemHeart (pRVAD)
[75]. In both cases, the chosen cardiac output was a
maximum of 3.5L/min with mean between 2 and 3L/min.
Successful bilateral percutaneous assist device support was
accomplished via pRVAD with TandemHeart and left IABP
counterpulsationinanacutebiventricularmyocardialinfarc-
tion. The patient was under mechanical support for 48 hours
and was discharged eight days after the procedure [76].
Finally, biventricular support with pRVAD TandemHeart
and pLVAD with Impella Recover LP 2.5 allowed complete
recovery of a patient with severe cardiac allograft rejection
[14]. Admittedly, these are isolated cases in which last resort
complex and potentially dangerous procedures were initi-
ated. They nevertheless emphasise the life-saving potential of
pVADs.
5. Extracorporeal Life Support
Extracorporeal life support encompasses life support devices
including oxygenation, carbon dioxide removal, and hemo-
dynamic support. It is a form of cardiopulmonary bypass
allowing either lung, or both lung and heart support.
The basic circuit consists of a venous cannula harvesting
deoxygenated blood, a 4000rpm centrifugal pump with
u pt o7 L / m i nh i g hﬂ o w ,am e m b r a n eo x y g e n a t o r ,ah e a t
exchanger, and a returning cannula with oxygenated blood.
Two distinct conﬁgurations exist, one being a venovenous
(VV) cannulation bypassing the lungs and allowing support
in respiratory failure. The other being the venoarterial (VA)
cannulation where the oxygenated blood is pumped back
to the arterial system bypassing lungs and heart providing
not only respiratory but also hemodynamic support (see
Figure 4). Only the veno-arterial cannulation within the
spectrum of hemodynamic support will be considered here.
Technically, the extracting, 22–30-Fr venous cannula is
inserted using the Seldinger technique in the right common
femoral vein. The 15–23-Fr arterial cannula is placed in the
right common femoral artery and maintained in the iliac
artery. A supplementary arterial cannula may be inserted
distal to the femoral artery cannula to prevent lower limb
ischemia. If the lower limb vessels are unsuitable, right
common carotid artery or axillary artery cannulation is
possible.
Anticoagulation is achieved through continuous unfrac-
tionated heparin infusion with recommended ACT between
210 and 230 seconds. Platelet count should be maintained
greater than 100,000/microL as sheer forces and exposure
to foreign body continuously consume them. The duration
of support is classically described from 15 to 21 days
for femoral access and up to two months for central
thoracic access. Complications include local hemorrhage,
thromboembolism, lower limb ischaemia, ischemic and
hemorrhagic stroke, haemolysis, and infections.
Special attention must be made when cardiac function
recovers with ﬂow competing against the ECLS returning
blood in the aorta. In case of persistent respiratory failure,
the Harlequin syndrome classically describes a blue-headed
( d e o x y g e n a t e db l o o dd i r e c t e dt ot h eu p p e rb o d y )a n dr e d -
legged patient (hyperoxygenated blood to the lower body).
Switch from VA to VV ECLS may then be needed.6 Minimally Invasive Surgery
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Figure 4: Example of extracorporeal life support (ECLS). CARDIOHELP System (MAQUET, Cardiopulmonary AG, Germany). Minimised
hand-held ECLS with representation of a femorofemoral, venoarterial cannulation. Deoxygenated blood is harvested in the femoral vein and
pumped back to the iliac artery after having passed through the oxygenating membrane and the heat exchanger.
Indications range from severe refractory cardiogenic
shock [77], cardiac arrest [78] to failure to wean from car-
diopulmonary bypass in cardiac surgery [79] and ﬁnally as a
bridge [80] to either transplantation or sVAD. Relative con-
traindications are similar to those for VAD as stated above.
To date, there have been no randomised trials assessing
ECLS eﬃcacy in hemodynamic support but observational
studies exhibit promising results.
Two studies showed a beneﬁt of ECLS performed in
cardiac arrest [81, 82]. Short-term and 6-month survival
rate were signiﬁcantly increased in 59 and 85 patients under
ECLS-CPR as compared with conventional CPR. Another
study evaluated the outcomes of 81 patients who beneﬁted
from ECLS in severe refractory cardiogenic shock with
long-term survival rates of 36% [77]. In comparison to
biventricular assist devices, ECLS was as eﬀective in recovery
of fulminant myocarditis yet with faster renal and hepatic
recovery [83].
Newer, minimised ECLS systems such as the ELS-System
and Cardiohelp (both from MAQUET Cardiopulmonary
AG, Germany) have been developed allowing rapid insertion
and facilitated interhospital transport [84]. One case report
showed safe application of Cardiohelp in 6 patients. Inter-
hospital transport was done by car or helicopter and survival
rate was 100% [85].
6.FutureDevices
Another promising device not commercially available is the
Reitan Catheter Pump (RCP; Kiwimed Ltd.). It consists of a
catheter-mounted pump-head with a foldable propeller and
surrounding cage. Positioned in the descending aorta, the
pump creates a pressure gradient, reducing afterload and
enhancing organ perfusion. One study conﬁrmed its safety
in 11 high-risk PCI patients [86]. Beneﬁts on hemodynamic
parameters especially cardiac output have not been shown in
humans.
7. Conclusion
Acute heart failure and cardiogenic shock, regardless the
cause, still have a dreadful outcome. Current management
includes use of inotropic support and/or IABP. In the
past decade, pVAD and ECLS have completed this arma-
mentarium with which one can tackle these conditions. A
true technological advance, proven to restore and maintain
perfusion pressures. Although better hemodynamic param-
eters are interesting, improved clinical outcome has yet to
be demonstrated. Ultimately, complications arising from
insertion and costs further broaden the debate. In this sense,
pVADs and ECLS are no plot devices, and the seemingly
inextricable problem of acute heart failure is not likely to be
solved with a sole object.
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